North America, Europe, Asian Pacific, Latin America, Middle East and Africa, and ROW
Preclinical Imaging (In-VIVO) Market is expected to reach 1401.86 million by 2027 at CAGR of 4.92%. Preclinical imaging is medical process of visualization of living animals for purpose of research , such as new medical procedure and drug development . In vivo imaging has been described as bridging the gap between in vitro exploratory and in vivo clinical research, facilitating the direct and fast transfer of preclinical studies on animal models to clinical investigation in man. Imaging modalities have long been crucial to the researcher in observing changes, either at the organ, tissue, cell, or molecular level, in animals responding to physiological or environmental changes.
In application aspect, vivo imaging is increasingly deployed across the drug development process, with applicability in target identification, compound optimisation and pre-Phase I studies. In vivo imaging has been described as bridging the gap between in vitro exploratory and in vivo clinical research, facilitating the direct and fast transfer of preclinical studies on animal models to clinical investigation in man. The key diseases/therapeutic areas targeted with in vivo preclinical imaging by survey respondents were oncology/cancer (70% targeting). This was followed by inflammatory disease/autoimmune (36% targeting), neurology / CNS / neurodegeneration/ pain (32% targeting) and then cardiovascular (25% targeting)
Imaging modalities that are non-invasive and in vivo have become especially important to study animal models longitudinally. The most suitable modalities for small-animal in vivo imaging applications are based on nuclear medicine techniques (essentially, positron emission tomography [PET] and single photon emission computed tomography [SPECT]), optical imaging (OI), computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy imaging (MRSI), and ultrasound
Geographically, Preclinical Imaging (In-VIVO) Market categorised in North America, Europe, China, Japan, South East Asia, India and Rest of World. North America holds the highest sale volume of market. Increased in Pharmaceutical research, New development in biotechnology, government support for various research work and advancement in technology are the prime factor driving the Preclinical Imaging (In-VIVO) Market globally. Europe and Asia –Pacific market is expected to grow at higher CAGR in forecasted years. African market expected to grow at lower rate while Middle East and South American market is expected to show constant growth rate.
Preclinical Imaging (In-VIVO) Market: Techniques Type
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Preclinical Imaging (In-VIVO) Market:
PerkinElmer
Bruker Corporation
FUJIFILM Holdings
Mediso
MILabs B.V.
MR Solutions
Aspect Imaging
LI-COR Biosciences
Trifoil Imaging
Miltenyi Biotec
Geographical analysis of Preclinical Imaging (In-VIVO) Market:
North America
U.S.A
Canada
Europe
France
Germany
Spain
UK
Rest of Europe
Asia Pacific
China
Japan
India
South East Asia
Latin America
Brazil
Middle East and Africa
Preclinical Imaging (In-VIVO) Market Report delivers comprehensive analysis of :
Market Forecast for 2018-26
Market growth drivers
Challenges and Opportunities
Emerging and Current Market trends
Market player Capacity, Production, Revenue (Value)
